Wyeth Pharmaceuticals has announced that it welcomes the decision by the governments of a number of donor countries to initiate a pilot advanced market commitment to aid the delivery of pneumococcal conjugate vaccine to developing countries.
The company notes that it is dedicated to the protection of young children and infants against pneumococcal disease, with its pneumococcal conjugate vaccine Prevenar (absorbed pneumococcal saccharide conjugated vaccine) part of many childhood immunisation programmes worldwide.
Wyeth adds that it currently has a 13-valent pneumococcal conjugate vaccine in clinical development to target additional serotypes.
Bernard Poussot, president, chief operating officer and vice chairman of Wyeth, said: "We join the International Federation of Pharmaceutical Manufacturers and Associations and the global community in commending the donor countries."
He added that this financial backing would provide much-needed awareness to pneumococcal disease, with the company looking forward to working with global partners in protecting children against the effects of pneumococcal disease.
In November 2006, Wyeth announced its support for the decision by the GAVI Alliance to approve funds to assist in the introduction of pneumococcal conjugate vaccine in eligible countries.
Wyeth noted that its investigational 9-valent vaccine had demonstrated a 71 per cent reduction in cases of the disease in a trial held in Gambia.See all the latest jobs in Pharmaceutical